Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Mar;71(3):e30825.
doi: 10.1002/pbc.30825. Epub 2023 Dec 25.

Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALL

Paul E George  1   2   3 , Nicholas P DeGroote  1 , Michaela Henderson  1   2 , Katherine Jordan  1 , Christiana Ziworitin-Ogola  1   2   3 , Sharon M Castellino  1   2 , Tamara P Miller  1   2
Affiliations
Multicenter Study

Missing the mark? Exploratory analysis of the 10-year-old cutoff as an independent marker of high-risk disease in pediatric B-ALL

Paul E George et al. Pediatr Blood Cancer. 2024 Mar.

Abstract

This single-center, retrospective study evaluated age as a risk factor for relapsed/refractory disease and/or death in 153 children with B-cell acute lymphoblastic leukemia. The study sample included children near the 10-year age cutoff for high-risk disease (6.0-13.9 years at diagnosis) and without other high-risk features (high white cell count, unfavorable cytogenetics). Children 10.0-13.9 years treated per high-risk protocols did not have inferior outcomes compared with children aged 6.0-9.9 years initiating treatment per standard-risk protocols. The study indicates that, in the era of cytogenetics, an age threshold of 10 years might not be an independent prognostic marker. Multicenter analyses are needed.

Keywords: Age; B-cell acute lymphoblastic leukemia; outcomes; pediatric.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

References

    1. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol, 1996. 14: 18–24. - PubMed
    1. Wang Y, Huang J, Rong L, Wu P, Kang M, Zhang X, Lu Q, Fang Y. Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database. Oncotarget, 2016. 7: 83767–83774. - PMC - PubMed
    1. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, Camitta BM. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood, 2008. 111: 5477–5485. - PMC - PubMed
    1. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig W-D, Riehm H, Schrappe M. Prognostic Impact of Age in Children and Adolescents with Acute Lymphoblastic Leukemia: Data from the Trials ALL-BFM 86, 90, and 95. Klin Pädiatr, 2005. 217: 310–320. - PubMed
    1. Chessells JM, Veys P, Kempski H, Henley P, Leiper A, Webb D, Hann IM. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol, 2003. 123: 396–405. - PubMed

Publication types

MeSH terms

LinkOut - more resources